The breakthrough technology of DeepSeek has significantly accelerated the application of AI in the medical industry, opening up diverse application scenarios for AI + healthcare. IVD companies are leveraging AI-empowered products and services to reduce costs and increase efficiency. New algorithms are helping to speed up the integration and application of big data, making early disease screening, risk prediction, and personalized health management promising application areas. Companies with a first-mover advantage in data accumulation and analysis are expected to lead the way.
AI + Diagnostics: Upgrading Intelligent Testing
- AI-Enhanced Equipment for Smart Laboratories : AI is driving the intelligent upgrade of products and services in the IVD industry. For example, the iXLAB smart laboratory system has comprehensively upgraded laboratory management, intelligent testing, and research support. It has increased management process response speed by 80 %, reduced human-error rates by 65 %, and doubled the speed of clinical decision-making responses.
- AI Software for Doctors : On February 11th, the cervical cytology digital pathology image-assisted diagnosis software invested by Wondfo’s CellsVision officially obtained a Class III medical device registration certificate from the NMPA. This is the first Class III certificate for auxiliary diagnosis in the field of cervical cytology. By assisting in slide reading through AI, it significantly improves diagnostic efficiency and accuracy, addressing the shortage of pathologists.
- AI-Empowered C-End Health Management : For example, Sinocare’s (SHE: 300298) CGM provides diabetes full-course management services for patients through precise monitoring and intelligent analysis.
AI + ICL: Improving Quality and Efficiency to Accelerate Data Value Conversion
- External Services : In 2024, KingMed Diagnostics and Dian Diagnostics (SHE: 300244) both released large-scale medical testing models. For instance, KingMed Diagnostics’ intelligent application Xiaoyu Medical provides one-stop interactive services in medical testing project consultation, intelligent report interpretation, and testing project recommendation. Relying on its service platform KMC with over 520,000 registered users, it has reached doctors and since its launch at the end of August 2024, its monthly usage has approached 100,000 times.
- Internal Operations : AI-empowered full-process digital solutions are used to enhance laboratory automation and intelligent operations, reducing costs and increasing efficiency.
- Data Value Conversion : In 2024, KingMed Diagnostics launched five data products on the Guangzhou Data Exchange, with the breast cancer data report being the first to complete in-field transactions. As more data is developed and products are launched, future cooperation with research institutions, drug and device manufacturers, and commercial insurance companies is expected to further expand commercialization opportunities.
AI + Multi-omics Analysis: Accelerating Clinical Application
New AI algorithms help improve the accuracy and efficiency of data analysis in genomics and other fields, while reducing analysis costs, thus accelerating clinical application. With the continuous accumulation of big data and algorithm optimization, it is expected to achieve precise matching of individual health management needs and disease risk prediction in the future. By integrating multi-dimensional data such as genomics, proteomics, and metabolomics, the development and application of early-screening products for tumors and other diseases are expected to be promoted. For example, in September 2024, BGI (SHE: 300676) launched its self-developed generative bio-intelligence (GBI ALL) innovation paradigm, including the clinical gene testing multi-modal large model GeneT and the genomic consultation platform ChatGeneT for the public, accelerating business transformation and upgrading.-Fineline Info & Tech
Leave a Reply